Clinical Trial Update: Safety and Efficacy of TeaRx Xa Factor Direct Inhibitor Versus Enoxaparin as a Venous Thromboembolic Events (VTE) Prevention Following Total Knee Replacement [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing TeaRx's Xa factor direct inhibitor to enoxaparin for prevention of venous thromboembolism after total knee replacement has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Venous Thromboembolism

Drugs mentioned

• Enoxaparin (enoxaparin sodium)
• TeaRx Xa Factor Direct Inhibitor (Factor Xa direct inhibitor)

Snippet

Sponsor: TeaRx LLC | Conditions: Total Knee Replacement | Phase 2 | Status: COMPLETED